Mangoceuticals Reports $456,021 Revenue Decline and $20.6 Million Net Loss for 2025

Mangoceuticals, Inc. reported revenues of $456,021 for the year ended December 31, 2025, a decrease from $615,873 in the previous year. This decline was attributed to issues during the transition to a new telehealth platform. The company's cost of revenues decreased to $54,422 from $93,296, while related party costs of revenues, representing payments to Epiq Scripts, increased slightly to $151,213 from $142,613. The company's net loss for the year was $20.6 million, compared to $8.7 million in the prior year.

Operating expenses significantly impacted the company's financial performance. General and administrative expenses increased to $3.8 million from $3.0 million, primarily due to consulting and accounting fees. Salaries and benefits also rose to $1.3 million from $1.1 million due to new management and staff engagements. Advertising and marketing expenses decreased to $822,860 from $1.5 million, while investor relations expenses increased substantially to $1.6 million from $453,749. Stock-based compensation also saw a significant increase, reaching $10.8 million compared to $2.4 million in the previous year.

Key operational developments included a reverse stock split at a ratio of 1-for-15, effective October 16, 2024, aimed at regaining compliance with Nasdaq's minimum bid price requirement. The company also entered into a Parent Subsidiary Contribution Agreement, transferring substantially all of its assets to Mango & Peaches Corp., a wholly-owned subsidiary. A Master Distribution Agreement was signed with Propre Energie Inc. to license intellectual property for plant-based formulations, with plans to commence operations in the 2nd quarter of 2026. Additionally, Mango DAT, LLC, a wholly-owned subsidiary, entered into a Master Services Agreement with Cube Operations LLC to support a Solana-focused digital asset treasury strategy.

As of December 31, 2025, Mangoceuticals had $1.5 million in cash and a working capital of $0.7 million. The company's plan for the next 12 months involves continuing its marketing and management strategies, enhancing its platform, and exploring strategic acquisitions. However, the company acknowledges the need for additional funding to sustain operations and meet public company obligations. The company is exploring various financing options, including equity and debt offerings, but there is no guarantee that such funding will be available on favorable terms. The company's independent registered public accounting firm included an explanatory paragraph in its report on the consolidated financial statements as of December 31, 2025, regarding the company's ability to continue as a going concern.